+1-888-308-5802     
News Contact Us

Innate Pharma and AstraZeneca extend oncology development partnership

Author : Pankaj Singh | Published Date : 2018-10-24 

Innate Pharma SA has reportedly announced a multi-term agreement with AstraZeneca and its global biologics research and development subsidiary, MedImmune. Innate looks to building on an existing collaboration to accelerate the oncology portfolio of each company and bring new medicines to patients faster.

Apparently, Innate will be able to develop its commercial footprint and solidify its capability to invest in its immuno-oncology (IO) pipeline and R&D platform. It will also enrich the IO portfolio of AstraZeneca with preclinical and clinical potential new medicines.

As part of the agreement, Innate is licensing the EU and US commercial rights to AstraZeneca’s Lumoxiti (moxetumomab pasudotox-tdfk) which was recently FDA-approved for hairy cell leukemia ("HCL"). AstraZeneca, in turn, will obtain full oncology rights to monalizumab, the first-in-class humanized anti-NKG2A antibody. AstraZeneca further gains option rights to four pre-clinical molecules from the pipeline of Innate along with IPH5201, an antibody targeting CD39.

Chief Executive of Innate Pharma, Mondher Mahjoubi, stated that the company is transitioning to become a fully-integrated biotech focused on oncology. The company is addressing significant unmet medical needs like relapsed/refractory hairy cell leukemia, and Lumoxiti is a therapeutic innovation for patients suffering from these diseases, he added.

Mahjoubi said the company’s commercial team will focus on rare cancers and generate more value with the development of its hemato-oncology proprietary pipeline. Moreover, the decision of AstraZeneca to collaborate on IPH5201 and four yet to be selected molecules, in addition to obtaining full oncology rights to monalizumab justifies the strength of Innate’s oncology pipeline, he mentioned.

Chief Executive of AstraZeneca, Pascal Soriot, said that the expanded alliance with Innate enables AstraZeneca to explore the potential of next generation immuno-oncology pathways, and further strengthen its leadership in immuno-oncology with Innate’s world-class scientific team. This collaboration also secures long-term commercialization of Lumoxiti through dedicated focus and investment by Innate.

For the record, AstraZeneca will acquire an equity stake of 9.8% in Innate Pharma via 6,260,500 new shares issued to AstraZeneca at €10 per share, under the long-term collaboration among the two companies.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Datadog launches partner program to support channel partners in ANZ

Published Date: 2020-01-18         Author: Pankaj Singh

Datadog, the global monitoring and cloud-scale analytics platform for developers, IT teams, and business users, recently announced the launch of a new partner program, expanding its support for channel partners in Australia & New Zealand. The Datadog Partner Network will offer a structured platf... Read More

Banco Sabadell and TSB ink a cloud services contract with IBM

Published Date: 2020-01-17         Author: Pankaj Singh

Banco Sabadell, a Spain-based banking group, has inked a ten-year agreement with IBM to advance its hybrid cloud strategy. Sources cite that this deal is intended to streamline Sabadell’s dispersed technological infrastructure to move and manage data, services, and workflows across multip... Read More

NI partners with Braemac to broaden its Australia & New Zealand market

Published Date: 2020-01-16         Author: Pankaj Singh

NI, a Texas based provider of software defined platform that helps accelerate productivity, innovation and discovery, has reportedly announced that Braemac would now be the authorized distributor of NI products in Australia and New Zealand. Braemac, an authorized distributor of NI, would now wide... Read More

© 2020 Fractovia. All Rights Reserved